Maintenance Rituximab for Follicular Lymphoma

Share this content:
A recent meta-analysis including patients from 7 trials shows that MR improves overall survival among all patients regardless of patient and disease characteristics.
A recent meta-analysis including patients from 7 trials shows that MR improves overall survival among all patients regardless of patient and disease characteristics.

The approval of maintenance with rituximab (MR) for 2 years following response to an induction with rituximab-chemotherapy (R-chemotherapy) for patients with newly diagnosed follicular lymphoma was based on results of the PRIMA study (ClinicalTrials.gov Identifier: NCT00140582).1

Rituximab maintenance has been shown to improve progression-free survival, though overall survival results are inconclusive. A recent meta-analysis including patients from 7 trials shows, however, that MR improves overall survival (vs observation) among all patients regardless of patient and disease characteristics.2 

The trials contributed data from 2315 patients for this meta-analysis. Most patients received R-chemotherapy (74%) or chemotherapy as induction therapy followed by MR or observation. Induction chemotherapy included cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) among 62% of patients, cyclophosphamide, vincristine, and prednisone (CVP) among 23% of patients, and fludarabine among 15% of patients. Of the included patients, 1145 patients received MR and 1170 patients did not.

The median follow-up was 6 years; overall survival was significantly improved for patients on MR, reducing the risk of death by 21%. Median overall survival in the MR and observation groups was 12 years and 11.5 years, respectively.

Significant overall survival improvements were not seen among patients receiving MR after first-line induction versus observation. With a hazard ratio of 1.049, patients who received first-line rituximab in their induction regimen were likely to have similar overall survival rates from MR compared with observation only.

RELATED: Hodgkin Lymphoma Survivors at Risk for Second Cancers

Among patients receiving MR after second-line induction with chemoimmunotherapy or chemotherapy, however, there was a significant benefit in overall survival, with a 30% reduced risk for death. Similar results were seen with patients who received only chemotherapy as induction therapy.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters